Holen Sie sich die Stockscreener-App
10.39
4.84%
0.48
Handel nachbörslich:
10.64
0.25
+2.41%
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Candlestick signals on Arcus Biosciences Inc. stock today2025 Market Outlook & Momentum Based Trading Signals - Newser
Using RSI to spot recovery in Arcus Biosciences Inc.Gap Down & Weekly High Potential Alerts - Newser
Identifying reversal signals in Arcus Biosciences Inc.July 2025 PostEarnings & AI Based Buy/Sell Signal Reports - Newser
Will Arcus Biosciences Inc. Sustain Its Chart Breakout2025 Top Gainers & Fast Entry Momentum Trade Alerts - beatles.ru
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 - MSN
Will breakout in Arcus Biosciences Inc. lead to full recoveryQuarterly Trade Summary & Fast Entry High Yield Tips - Newser
Arcus Biosciences’ SWOT analysis: stock’s potential hinges on HIF-2alpha data - Investing.com
Jim Cramer Recommends Uranium Energy Corp., Warns Against Overreliance on Arcus Biosciences. - AInvest
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus - Benzinga
What machine learning models say about Arcus Biosciences Inc.Weekly Profit Report & Expert Approved Trade Ideas - Newser
Why Arcus Biosciences Inc. stock attracts strong analyst attentionWeekly Trade Analysis & Fast Moving Stock Trade Plans - Newser
New Product Launches: Will They Boost Arcus Biosciences Inc. Stock in 2025July 2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
What institutional flow reveals about Arcus Biosciences Inc.Earnings Growth Report & Risk Managed Investment Entry Signals - Newser
Will Arcus Biosciences Inc. Hold Gains Into CloseReliable Alerts for Daily Stock Movers Released - beatles.ru
Arcus Biosciences (NYSE:RCUS) Upgraded at Wall Street Zen - Defense World
How to escape a deep drawdown in Arcus Biosciences Inc.Free Smart Trade Plans With Risk Protection - Newser
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cantor Fitzgerald Issues Positive Forecast for RCUS Earnings - Defense World
Wedbush Forecasts Lower Earnings for Arcus Biosciences - Defense World
Q3 EPS Forecast for Arcus Biosciences Reduced by Analyst - Defense World
Custom watchlist performance reports with Arcus Biosciences Inc.AI Volatility Forecast and Risk Monitor - Newser
Arcus Biosciences Q2 Earnings and Catalysts Ahead: A Risky Buy for 12 Months - AInvest
Arcus BiosciencesA Risky Buy Ahead Of Pivotal, Catalyst Rich 12 Months (NYSE:RCUS) - Seeking Alpha
Trapped Investors in Arcus Biosciences Inc. Await Breakout SignalNews Based Entry Opportunity Alerts Detected - beatles.ru
Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Zurcher Kantonalbank Zurich Cantonalbank Buys 2,524 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Inc. Stock Recovery Path — Analyst BreakdownReal Time Stock Movement Analysis Indicates Breakout - beatles.ru
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Arcus Biosciences Tops Revenue Forecasts And Drives Pipeline Growth - Finimize
Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers - TipRanks
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $14 to $52 - 富途牛牛
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) | - GuruFocus
H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Morgan Stanley Lifts Price Target on Arcus Biosciences to $23 From $22, Keeps Overweight Rating - MarketScreener
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Arcus Biosciences Reports Strong Q2 2025 Results - TipRanks
Arcus Biosciences earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Arcus Biosciences Q2 revenue beats analyst expectations - MarketScreener
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update - Stock Titan
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Is Arcus Biosciences (NYSE:RCUS) Using Debt In A Risky Way? - 富途牛牛
When is Arcus Biosciences Inc. stock expected to show significant growthIdentify undervalued stocks ready to soar - Jammu Links News
How volatile is Arcus Biosciences Inc. stock compared to the marketTremendous gains - Jammu Links News
What are the technical indicators suggesting about Arcus Biosciences Inc.Free Wealth Planning Blueprint - Jammu Links News
What institutional investors are buying Arcus Biosciences Inc. stockHigh-yield investments - Jammu Links News
Should I hold or sell Arcus Biosciences Inc. stock in 2025Unlock powerful portfolio management tools - Jammu Links News
How does Arcus Biosciences Inc. compare to its industry peersOutstanding capital appreciation - Jammu Links News
What are the latest earnings results for Arcus Biosciences Inc.Outstanding risk-reward balance - Jammu Links News
Why is Arcus Biosciences Inc. stock attracting strong analyst attentionRealize consistent double-digit growth - Jammu Links News
Does Arcus Biosciences Inc. stock perform well during market downturnsTremendous gains - Jammu Links News
What catalysts could drive Arcus Biosciences Inc. stock higher in 2025Free Stock Movement Tracking - Jammu Links News
Arcus Biosciences’ Pancreatic Cancer Drug Quemliclustat Receives Orphan Drug Designation from FDA - MSN
How does Arcus Biosciences Inc. generate profit in a changing economyPost Market Planner That Work - Jammu Links News
Arcus Biosciences Advances Phase 1 Study of AB521 in Cancer Treatment - TipRanks
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):